Familial glucocorticoid deficiency (FGD)
Overview
Familial glucocorticoid deficiency (FGD) is a rare, autosomal recessive genetic disorder where the adrenal glands fail to produce cortisol despite high levels of adrenocorticotropic hormone (ACTH). It is characterized by isolated glucocorticoid insufficiency without mineralocorticoid deficiency, resulting in severe hypoglycemia, hyperpigmentation, failure to thrive, and recurrent infections.
Symptoms
Hypoglycemic Seizures: Low blood sugar frequently causes seizures (convulsions), which can lead to coma or death if untreated.
Hyperpigmentation: Excess ACTH overstimulates skin receptors, causing progressive darkening of the skin and gums, often most noticeable in skin creases, scars, or inside the mouth.
Failure to Thrive & Growth Delay: Children may fail to gain weight or grow at the expected rate due to prolonged hypoglycemia and poor metabolism.
Recurrent Infections: Patients, particularly older children, often suffer from frequent or lingering infections.
Gastrointestinal Distress: Low cortisol can cause vomiting, chronic nausea, diarrhea, constipation, and unexplained abdominal or flank pain.
Neurological Impairment: Repeated or prolonged hypoglycemic episodes in early life can cause irreversible neurological damage, learning difficulties, and intellectual deficits.
Causes
\(MC2R\) Gene Mutations (FGD Type 1): Accounts for roughly \(25\%\) of cases. It produces the ACTH receptor; mutations prevent the receptor from traveling to the cell surface or binding to ACTH.
\(MRAP\) Gene Mutations (FGD Type 2): Accounts for \(15\%\) to \(20\%\) of cases. The Melanocortin 2 Receptor Accessory Protein (\(MRAP\)) is required to transport the ACTH receptor to the cell membrane.
\(NNT\) Gene Mutations: Accounts for about \(15\%\) of cases. The Nicotinamide Nucleotide Transhydrogenase (\(NNT\)) enzyme is involved in antioxidant defense. Mutations make the adrenal glands highly susceptible to oxidative stress.
\(MCM4\) Gene Mutations: Found predominantly in the Irish Traveler population. The Mini Chromosome Maintenance 4 (\(MCM4\)) gene is linked to DNA replication.
Other Associated Genes: Rare cases have also been linked to mutations in \(TXNRD2\), \(STAR\), and \(CYP11A1\)
Diagnosis
Diagnosis typically begins when a child presents with classic symptoms such as hyperpigmentation, severe hypoglycemia (low blood sugar), failure to thrive, and recurrent infections.
Early Morning Cortisol: Will be abnormally low or undetectable.
Plasma ACTH: Will be grossly elevated (often \(>1000\) pg/mL).
Electrolytes & Renin: Mineralocorticoid levels (e.g., aldosterone) and salt/water balance remain completely normal, which is crucial for ruling out standard Addison's disease.
ACTH Stimulation Test: Demonstrates that the adrenal glands fail to produce cortisol even when heavily stimulated by exogenous ACTH.
2. Genetic Testing
Because FGD is a monogenic autosomal recessive disorder, definitive diagnosis requires confirming a pathogenic variant in one of the genes responsible for ACTH resistance or adrenal development. The most common genetic culprits include:
MC2R: Mutations in the melanocortin 2 receptor gene (FGD Type 1).
MRAP: Mutations in the MC2R accessory protein gene (FGD Type 2).Other rarer forms involve mutations in genes like MCM4, NNT, or TXNRD2.
Treatment
Medication: Oral hydrocortisone is the standard treatment.
Pediatric Dosing: For children, a dose of approximately \(10 \text{ to } 12 \text{ mg/m}^2/\text{day}\) is typically required, divided into 2 to 3 regular doses throughout the day.
Adult Dosing: Adults generally require \(15 \text{ to } 25 \text{ mg/day}\), divided into two or three oral doses.
ACTH Levels: Suppressing elevated ACTH (adrenocorticotropic hormone) levels is incredibly difficult in FGD and should not be the primary goal of the treatment. Hydrocortisone dosing is adjusted based on clinical symptoms, growth velocity, and general well-being, rather than ACTH levels.
Mineralocorticoids: Unlike primary adrenal insufficiency (Addison's disease), aldosterone and renin levels are typically normal in FGD, meaning fludrocortisone replacement is generally not required.
Sick-Day Rules: During periods of physical stress—such as high fevers, infections, surgeries, or severe vomiting—patients require a "stress dose" of hydrocortisone. The standard dose is typically doubled or tripled depending on the severity of the illness to prevent an acute adrenal crisis.
Emergency Kit: Patients and their families must be equipped with injectable (parenteral) hydrocortisone for emergency situations and educated on how to administer it.
Medical Identification: Patients should carry a medical alert card or wear a medical bracelet indicating their reliance on glucocorticoids and their emergency needs.
Monitoring: Regular pediatric or endocrine follow-ups are essential to track growth patterns, electrolyte levels, and overall hormonal balance.
Vaccination: Routine vaccinations, including live attenuated vaccines, are entirely safe and recommended for children undergoing effective hydrocortisone replacement therapy.
Prognosis: When correctly diagnosed and managed, patients with FGD can expect normal neurological, physical, and sexual development.
Type of Doctor Department : An Endocrinologist

Comments
Post a Comment